Skip to main content

Table 2 Cervical cancer member characteristics by stage, diagnosed 2016–2020 (N = 1,866)

From: Increased healthcare costs by later stage cancer diagnosis

Stage

I

II

III

IV

n (%)a, b

1,300 (69.7%)

198 (10.6%)

215 (11.5%)

153 (8.2%)

Age, mean (SD), yearsb

58.6 (12.3)

57.5 (12.1)

60.4 (12.2)

59.9 (12.7)

Female Gender, n (%)b

1300 (100.0%)

198 (100.0%)

215 (100.0%)

153 (100.0%)

Insurance Type, n (%)a, b

 Commercial

97 (49.0%)

92 (42.8%)

73 (47.7%)

97 (49.0%)

 Medicaid

27 (13.6%)

14 (6.5%)

14 (9.2%)

27 (13.6%)

 Medicare Advantage

54 (27.3%)

82 (38.1%)

52 (34.0%)

54 (27.3%)

 Multiplec

0 (0.0%)

1 (0.5%)

0 (0.0%)

0 (0.0%)

 Unknown

20 (10.1%)

26 (12.1%)

14 (9.2%)

20 (10.1%)

Geographic Region, n (%)a, b

 Midwest

578 (44.5%)

87 (43.9%)

84 (39.1%)

65 (42.5%)

 Northeast

484 (37.2%)

64 (32.3%)

76 (35.4%)

50 (32.7%)

 South

114 (8.8%)

33 (16.7%)

32 (14.9%)

15 (9.8%)

 West

104 (8.0%)

12 (6.1%)

18 (8.4%)

18 (11.8%)

 Unknown

20 (1.5%)

2 (1.0%)

5 (2.3%)

5 (3.3%)

CCI, mean (SD)d

0.8 (1.2)

0.8 (1.3)

1.3 (1.7)

1.3 (1.6)

CCI, n (%)a, d

 0

447 (57.2%)

56 (57.7%)

42 (43.8%)

27 (36.5%)

 1

192 (24.6%)

21 (21.6%)

21 (21.9%)

24 (32.4%)

 2

81 (10.4%)

10 (10.3%)

13 (13.5%)

12 (16.2%)

  ≥ 3

62 (7.9%)

10 (10.3%)

20 (20.8%)

11 (14.9%)

  1. Charlson Comorbidity Index; SD Standard deviation
  2. a Percentages may not total to 100% due to rounding
  3. b Demographics were calculated at the time of cancer diagnosis
  4. c Individuals had insurance eligibility from multiple types during this period
  5. d CCI was calculated among subjects with 6 months of continuous insurance eligibility prior to their cancer diagnosis